Your new post is loading...
MaxCyte, Inc., a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announces the signing of a strategic platform license (SPL) with LG Chem Ltd., a globally diversified chemical company established in petrochemical, advanced materials and bio-technology, aiming to create new value for its customers based on science.
MaxCyte, Inc, a commercial cell engineering company specializing in the provision of platform technologies has a portfolio of instruments that are the next generation of advanced, clinically validated electroporation technology for complex and scalable cell engineering. Offering high transfection efficiency, seamless scalability and enhanced functionality, their ExPERT™ platform notably delivers the high-end performance essential to enable the next wave of biological and cell-based therapies. The company announced the signing of a strategic platform licence (SPL) with LG Chem Ltd. This company obtains non-exclusive clinical and commercial rights to use MaxCyte's flow electroporation technology and ExPERT™ platform. In return, MaxCyte is entitled to receive platform licensing rights and revenues related to the programme. LG Chem is thereby strengthening its anti-cancer business through the advanced construction of cellular drug platform technologies. LR19023, its next-generation CAR-T cell therapy, is currently in preclinical stage and under development as a solid anti-cancer therapeutic.